Document is current

Article History

Received: 29 May 2024

Accepted: 10 November 2024

First Online: 24 November 2024

Declarations

:

: Takahisa Hirose received research funds from Mitsubishi Tanabe Pharma Corporation, Sumitomo Dainippon Pharma Co., Ltd., and Nippon Boehringer Ingelheim Co., Ltd., and lecture fees from Sanofi K.K., Eli Lilly Japan K.K., Novo Nordisk Pharma Ltd., MSD K.K., AstraZeneca K.K., Mitsubishi Tanabe Pharma Corporation, Kowa Company, Limited, Kissei Pharmaceutical Co., Ltd., Abbott Japan LLC., and Sumitomo Dainippon Pharma Co., Ltd.; Fukumi Yoshikawa received lecture fees from Novo Nordisk Pharma Ltd. The funders had no role in the study design, data collection and analysis, decision to publish, or manuscript preparation. Ayako Fuchigami, Yuuki Kojimahara, Mariko Higa, Takamasa Ichijyo, Hiroshi Uchino, and Kayoko Ikehara declare that they have no conflict of interest.

: The protocol for this research project has been approved by the Ethics Committee of Toho University Omori Medical Center (Approval No. M23096_22101_21282, Last Updated 2023/07/26) and conforms to the provisions of the Declaration of Helsinki. This study was registered in the University Hospital Medical Information Network Clinical Trial Registry (registration number: UMIN 000048859, 2022/09/12).

: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and/or with the Helsinki Declaration of 1964 and later versions. Informed consent, or a substitute for it, was obtained from all individuals for being included in the study.

: This article does not contain any studies with human or animal subjects performed by any of the authors.

: Informed consent was obtained from all participants.